| 19.59 0.2 (1.03%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 24.88 | 1-year : | 29.06 |
| Resists | First : | 21.3 | Second : | 24.88 |
| Pivot price | 19.01  |
|||
| Supports | First : | 17.46 | Second : | 15.09 |
| MAs | MA(5) : | 19.66 |
MA(20) : | 18.37 |
| MA(100) : | 16.11 |
MA(250) : | 14.12 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 70.1 |
D(3) : | 71.8 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 21.3 | Low : | 9.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KALV ] has closed below upper band by 38.3%. Bollinger Bands are 46.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 20.09 - 20.23 | 20.23 - 20.34 |
| Low: | 19.03 - 19.18 | 19.18 - 19.29 |
| Close: | 19.4 - 19.63 | 19.63 - 19.8 |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Mon, 13 Apr 2026
How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data - simplywall.st
Sun, 12 Apr 2026
KALV SEC Filings - Kalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 08 Apr 2026
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
Tue, 07 Apr 2026
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV) - Seeking Alpha
Thu, 02 Apr 2026
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wed, 25 Mar 2026
EKTERLY drives $49.1M revenue as KalVista (Nasdaq: KALV) reports net loss - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 136.8 (%) |
| Shares Short | 19,430 (K) |
| Shares Short P.Month | 19,790 (K) |
| EPS | -3.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | -223.2 % |
| Operating Margin | -21.3 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.36 |
| Sales Per Share | 1.43 |
| EBITDA (p.s.) | -3.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -122 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.98 |
| PEG Ratio | 0 |
| Price to Book value | -391.8 |
| Price to Sales | 13.62 |
| Price to Cash Flow | -8.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|